ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.
about
Mutant p53 and ETS2, a Tale of ReciprocityGlobal gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progressionIn Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer.The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells.Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis.PDEF is a negative regulator of colon cancer cell growth and migrationIntegrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer modelsRegulation of the microRNA 200b (miRNA-200b) by transcriptional regulators PEA3 and ELK-1 protein affects expression of Pin1 protein to control anoikisMultiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease.Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer.Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate CancerLaminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.Eureka! Ets a target for fibrosis!NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.The transcription factor MEF/Elf4 is dually modulated by p53-MDM2 axis and MEF-MDM2 autoregulatory mechanism.Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.Tracing the path of cancer initiation: the AA protein-based model for cancer genesis
P2860
Q26765746-53426857-FCB3-4C13-9FE6-FA9B3B26B0F1Q30157655-7BC0BBB2-7BD1-4747-8F48-656F9D3A8B3CQ34021008-7B76875B-7001-4C6B-8F27-63632F8C93B5Q34613397-429EF7BF-A62C-4439-A0FF-E8D16AF48CB9Q35082366-260798F9-472C-4385-9ED3-21391D6C7630Q35306040-DB29382D-44DD-44E5-94A7-65ED4B3F5C90Q35948104-943F34E6-8272-4CD7-966C-80F2A9429DFFQ36435777-F7F71344-3A18-49F1-B56B-59D3D949900BQ37289320-03B62825-50BF-4219-9A7A-6C359B23C187Q37967013-E2B9A090-3AA6-4D52-AFDA-62A7C25F205BQ37991651-519E4839-5F8C-41E7-A052-F04DE6930312Q38339382-432BC2D9-F249-4907-A8BA-2E712F6BA668Q39164084-43E2B231-8102-4FFB-8321-A6B61D33D610Q39941224-4357EDAA-69A6-4DD5-BCA6-17FB3EA5DBD7Q39986867-42F9B09C-F3A1-4EE8-8221-33FB32435582Q42042730-6631DE14-BEBB-4D85-9DB9-052B0C201219Q42917239-32F3EA6C-FBDC-4409-BFA2-3D74FC78BA52Q51416846-EC13EBFF-D8BD-466B-8FEE-EB834BB601D1Q54529505-365E494D-ECB0-4F90-8A08-62118599F4E3Q58770422-02C55833-0FB4-4159-B37F-285E7844A76E
P2860
ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ETS transcription factors: onc ...... c targets for prostate cancer.
@en
ETS transcription factors: onc ...... c targets for prostate cancer.
@nl
type
label
ETS transcription factors: onc ...... c targets for prostate cancer.
@en
ETS transcription factors: onc ...... c targets for prostate cancer.
@nl
prefLabel
ETS transcription factors: onc ...... c targets for prostate cancer.
@en
ETS transcription factors: onc ...... c targets for prostate cancer.
@nl
P2860
P356
P1476
ETS transcription factors: onc ...... c targets for prostate cancer.
@en
P2093
David P Turner
Dennis K Watson
P2860
P356
10.1586/14737140.8.1.33
P577
2008-01-01T00:00:00Z